可切除胰腺癌新辅助治疗的研究及指南解读,肯定还是否定?OACSTPCD
Research and guidelines interpretation of neoadjuvant therapy for resectable pancreatic cancer,promising or lim-ited?
作为一种系统性疾病,胰腺癌恶性程度高,复发转移率高,诊治与管理尤为困难.近年来随着新辅助治疗理念的不断推广,胰腺癌的治疗愈发强调在全流程、多方位管理中制定综合性、个性化治疗方案.然而,目前针对新辅助治疗在可切除胰腺癌中的应用尚存诸多争议.本文拟结合国、内外指南及最新研究进展,针对可切除胰腺癌病人实施新辅助治疗中的热点话题及相关争议进行探讨,以期推动新辅助治疗在可切除胰腺癌中的规范化应用.
As a systemic disease,pancreatic cancer is highly malignant and has a high rate of recurrence and metastasis,which makes it particularly difficult in diagnosis,treatment and management.In recent years,with the concept of neoadjuvant therapy deeply rooted in the hearts of the people,the treatment of pancreatic cancer has increasingly emphasized the development of comprehensive and individualized treatment schemes in the whole process and multi-dimensional management of pancreatic cancer patients.However,there still remain many controversies about the application of neoadjuvant therapy for resectable pancreatic cancer.This review intended to discuss the hot topics and related controversies in the implementation of neoadjuvant therapy for patients with resectable pancreatic cancer based on domestic and foreign guidelines and the latest research progress,which may vastly promote the standardized application of neoadjuvant therapy for resectable pancreatic cancer.
张太平;翁桂湖;刘悦泽
中国医学科学院北京协和医学院北京协和医院基本外科,北京 100730中国医学科学院北京协和医学院北京协和医院基本外科,北京 100730中国医学科学院北京协和医学院北京协和医院基本外科,北京 100730
临床医学
可切除胰腺癌新辅助治疗进展与争议规范化治疗
Resectable pancreatic cancerNeoadjuvant therapyProgress and controversiesStandardized treatment
《外科理论与实践》 2024 (1)
MYC/let-7/LAT2通路通过谷氨酰胺代谢和糖酵解调控胰腺癌化疗耐药的机制研究
1-4,4
国家自然科学基金(81972258,82272917)国家重点研发计划(2018YFE0118600)
评论